Patents by Inventor Vijay Vishesh Upreti

Vijay Vishesh Upreti has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240105341
    Abstract: A method for estimating tumor growth dynamics includes obtaining, by one or more processors, progression-free survival (PFS) data for a plurality of patients, the PFS data indicating (i) a plurality of observation times, and (ii) how many of the plurality of patients, at each of the plurality of observation times, had a PFS event within a most recent time window; determining, by the one or more processors and based on the PFS data, a population distribution for one or more patient-specific parameters; obtaining, by the one or more processors, measured tumor growth data for a particular patient subject to a drug treatment; estimating, by the one or more processors, tumor growth for the particular patient based on (i) the measured tumor growth data and (ii) the population distribution for the one or more patient-specific parameters; and causing, by the one or more processors, a display to present a visual indication of the estimated tumor growth for the particular patient.
    Type: Application
    Filed: September 21, 2023
    Publication date: March 28, 2024
    Inventors: Arya POURZANJANI, Khamir MEHTA, Vijay Vishesh UPRETI
  • Publication number: 20230174643
    Abstract: The present invention provides a method for the treatment of DLL3-positive cancer or SCLC, comprising administering to a subject in need thereof an anti-DLL3 agent at a dose of between about 0.3 mg to about 100 mg or between about 3 mg to about 200 mg, once every two weeks. Step dosing of the anti-DLL3 agent for the treatment of SCLC is also disclosed.
    Type: Application
    Filed: November 5, 2020
    Publication date: June 8, 2023
    Inventors: Marie-Anne Damiette Smit, Neelesh Soman, Vijay Vishesh Upreti, Mukul Minocha, Michael Liao, Aditya Shetty, Nooshin Hashemi Sadraei, Gataree Ngarmchamnanrith, Marc Anthony Yago
  • Publication number: 20230146593
    Abstract: The present invention relates to medical combination products comprising (i) at least one antibody construct comprising at least one domain which binds to a target antigen expressed on the surface of a cell and at least one other domain which binds to CD3 as well as (ii) at least one molecule that is inhibitor/antagonist of TNF/TNFR reducing TNF/TNFR signaling and/or an inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling, wherein a first dose of said inhibitor/antagonist is administered before administration of a first dose of said antibody construct. Furthermore, the invention provides therapeutic and preventive methods and medical uses of said combination products, as well as a kit comprising said at least one antibody construct and at least one antagonist/inhibitor of TNF or IL6 or its cognate receptor, wherein the interaction of said antagonist/inhibitor of TNF or an inhibitor/antagonist of IL6 with its cognate receptor reduces, mitigates, prevents, or treats cytokine release syndrome.
    Type: Application
    Filed: March 12, 2021
    Publication date: May 11, 2023
    Inventors: Sophia K. Khaldoyanidi, Dirk Nagorsen, Tara Arvedson, Suresh Agarwal, Vijay Vishesh Upreti, Steven Yea
  • Publication number: 20210139584
    Abstract: The present invention relates to the dosage and administration of anti-BCMA agents for the treatment of BCMA positive neoplasms. More specifically, the present invention relates to an antibody construct comprising a first domain which binds to BCMA, a second domain which binds to CD3 and a third domain which extends or enhances the half-life of the antibody construct, for use in the treatment or amelioration of a BCMA positive neoplasm, wherein the antibody construct is administered at a specified dose in at least one cycle. Moreover, the invention relates to a method for the treatment of a BCMA positive neoplasm comprising administering a specified dose of such antibody construct, and the use of such antibody construct for the manufacture of a medicament for the treatment of a BCMA positive neoplasm.
    Type: Application
    Filed: May 8, 2020
    Publication date: May 13, 2021
    Inventors: Alexander Minella, Vijay Vishesh Upreti, Julia Stieglmaier, Birgit Huber